NeuroVive share upgraded on OTC market in US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has
announced that the company’s share has been upgraded from trading on the OTC
Grey Market to OTC Pink in the US. The upgrade implies increased accessibility
and transparency, and improves the potential to attract interest from US
investors. This is in line with the company’s strategy to increase its presence
in the US, the world’s largest pharmaceuticals market.
Since March 2014, US investors have been able to trade electronically in the
NeuroVive share in USD on the OTC Grey Market without requiring a Swedish broker
or foreign exchange to SEK. However, shares on the OTC Grey Market are not
publicly quoted by all brokers, as they are not included in any of OTC Markets’
three main categories (OTC QX, OTC QB and OTC Pink), which means that the
regulatory requirements are less stringent and interest in the shares is usually
less extensive.

The upgrade to OTC Pink increases the NeuroVive share’s exposure in the US and
enables the company to publish press releases through OTC’s news service, for
example, which is likely to increase interest in the company generally and
attract more US investors.

”We’ve been focusing on increasing awareness of the NeuroVive share in the US,
by measures including strengthening the ownership structure, and our efforts are
now starting to pay off. In May, we completed a private placement aimed at high
-profile US institutional investors, and one of our objectives was to raise the
company’s status in North America,” commented NeuroVive’s CEO Mikael Brönnegård.

OTC Pink is subdivided into three categories based on the companies’ disclosure
requirements, and NeuroVive is included in the top tier Current Information
category.

”In addition to increased visibility and accessibility for US investors, the
upgrade also means that we’ll be subject to more stringent financial reporting
requirements. This implies increased transparency towards the market, which is
something we welcome,” Mikael Brönnegård continued.

The NeuroVive share is registered with OTC’s reporting service for foreign
securities in New York under the ticker symbol NEVPF:US. NEVPF’s share price can
be monitored at www.otcmarkets.com or through US brokers.

About OTC
OTC Markets Group’s Open, Transparent and Connected financial marketplaces
provide investors with the information necessary to intelligently analyze, value
and trade 10,000 US and global securities through the broker of their choice.
OTC consists of three main categories: OTC QX, OTC QB and OTC Pink and also
offers trading through OTC BB and OTC Grey Market.

About NeuroVive
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. NeuroVive’s drug
candidate CicloMulsion® is currently being evaluated in a phase III study on
treatment following myocardial infarct (CIRCUS), and in a phase II study on
acute kidney injury (CiPRICS). NeuroVive’s drug candidate NeuroSTAT® is
currently being evaluated in a phase II study on traumatic brain injury.
NeuroVive’s research programs also include development of drug substances for
the treatment of brain cell injury in stroke, and cellular protection and
mitochondria-related energy regulation diseases. NeuroVive’s shares are listed
on NASDAQ OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård or COO Jan Nilsson at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 26 June 2015, at 08.30 a.m. CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/NE
V 
PF/quot)